Search

Your search keyword '"Noriega-Concepción V"' showing total 3 results
Start Over Author "Noriega-Concepción V"
3 results on '"Noriega-Concepción V"'

1. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

Author

Suárez, E. U., Boluda, B., Lavilla, E., Tormo, M., Botella, C., Gil, C., Vives, S., Rodríguez, C., Serrano, J., Sayas, M. J., Martínez-Sánchez, P., Ramos, F., Bernal, T., Algarra, L., Bergua-Burgues, J. M., Pérez-Simón, J. A., Herrera, P., Barrios, M., Noriega-Concepción, V., Raposo-Puglia, J. A., Ayala, R., Barragán, E., Martínez-Cuadrón, D., Amigo, M. L., López-Lorenzo, J. L., Lázaro-García, A., Guimaraes, J. E., Colorado, M., García-Boyero, R., De Rueda-Ciller, B., Foncillas-García, M., Hong, A., Labrador, J., Alonso-Dominguez, J. M., and Montesinos, P.

Published
2024
Full Text
View/download PDF

2. Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation.

Author

Varela Gómez R, Vázquez Vázquez G, Noriega Concepción V, Galego García A, and Andón Saavedra C

Subjects
Adult, Allografts, Humans, Immunosuppression Therapy methods, Male, ABO Blood-Group System immunology, Anemia, Aplastic blood, Anemia, Aplastic immunology, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation, Immunosuppression Therapy adverse effects, Red-Cell Aplasia, Pure etiology, Red-Cell Aplasia, Pure immunology, Red-Cell Aplasia, Pure pathology, Red-Cell Aplasia, Pure therapy
Abstract

The literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition., (Copyright © 2017 King Faisal Specialist Hospital & Research Centre. Published by Elsevier B.V. All rights reserved.)

Published
2018
Full Text
View/download PDF

3. Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Author

Estévez-Loureiro R, Salgado-Fernández J, Marzoa-Rivas R, Barge-Caballero E, Pérez-Pérez A, Noriega-Concepción V, Calviño-Santos R, Vázquez-Rodríguez JM, Vázquez-González N, Castro-Beiras A, and Kaski JC

Subjects
Abciximab, Aged, Angioplasty, Balloon, Coronary, Antibodies, Monoclonal therapeutic use, Female, Follow-Up Studies, Humans, Immunoglobulin Fab Fragments therapeutic use, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction drug therapy, Myocardial Infarction surgery, Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors, Prognosis, Survival Analysis, Vascular Patency, Blood Platelets pathology, Myocardial Infarction blood, Myocardial Infarction therapy
Abstract

Background and Aims: Patency of infarct-related artery (IRA) before mechanical reperfusion with primary percutaneous coronary intervention (PPCI) has been associated with better prognosis in patients with ST-Elevation myocardial infarction (STEMI). Mean platelet volume (MPV) increases in STEMI patients and may be associated with increased thrombotic potential. In STEMI patients scheduled for PPCI we sought to assess whether mean platelet volume (MPV), as measured at admission, correlates with "spontaneous" reperfusion of the IRA and short-term clinical outcome., Methods: Blood samples were obtained on hospital admission in 617 consecutive patients (82% men; age 64 + or - 12 years) with STEMI, before PPCI. 372 (61%) patients were treated with the GP IIb/IIIa blocker abciximab. The main study endpoint was mortality at 30 days., Results: MPV was significantly lower in patients with basal TIMI flow grade 2 -3 compared to patients with TIMI grade 0-1 (median, 9 vs. 8.5 fL, p<0.0001). After adjustment, MPV remained an independent predictor of the patency of the IRA (OR 0.63, CI 95% 0.51 - 0.78). A cut off value of 8.95 fL had a predictive negative value of 82% to identify patients with patent IRA. Using this cut point, and after adjusting for confounders, MPV was an independent predictor of 30-day mortality (HR 2.92, CI 95% 1.36 - 6.29). When patients were subdivided according to abciximab use, MPV was a marker of worse outcome but only in patients who did not receive abciximab (HR 3.67, CI 95% 1.13 - 11.49)., Conclusion: An increased MPV is an independent predictor of both a patent IRA (TIMI flow 2 or 3 before PPCI) and 30-day mortality. This marker may be able to identify patients requiring more aggressive antiplatelet therapy.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results